Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 903 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT07566585RecruitingPhase 1
Safety study of BSB-2002 for relapsed or refractory AML with NPM1 mutation
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
St Louis, MissouriAges 18 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT07611838Recruiting
Predicting ABPA Recurrence Using Blood and Immune Markers
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
Jinan, ShandongAges 18–80 - NCT07616999Recruiting
Long-term follow-up study of early psychosis treatment
This study follows people who were part of an earlier research trial about medication management during their first psychotic episode. Researchers want to understand how those early treatment choices affected their recovery over the past 20 years.
Hong KongAges 18–65 - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT07635056RecruitingPhase 2
Natural killer cells for hard-to-treat neuroblastoma
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Cincinnati, OhioAges 1–39 - NCT06906419Enrolling by invitation
Knee surgery study for chronic kneecap dislocations
This study looks at how well a specific knee surgery (arthroscopic trochleoplasty) works over time for people who have had repeated kneecap dislocations. If you had this surgery between 2015 and 2023, your results could help doctors understand how to better treat this condition.
DrammenAges 18 years+ - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT05859997Enrolling by invitation
CAR-T cell therapy for active autoimmune disease flare-ups
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05706220Enrolling by invitation
Eye tests to measure visual speed in multiple sclerosis
This study tests how fast and how accurately your eyes process visual information and how eye movements look in people with multiple sclerosis. It may help researchers understand vision-related effects of MS using objective eye measurements.
Valladolid, ValladolidAges 18–80 - NCT05336188Enrolling by invitation
Smartphone help to prevent relapse in opioid use disorder
This study looks at whether a smartphone-based program can help people avoid relapse from opioid use disorder. Some participants may also do brain scans to better understand the brain changes behind relapse prevention.
Little Rock, ArkansasAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Birmingham, AlabamaAges 18 years+ - NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
Miami, FloridaAges 18 years+
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 903 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.